Search results for " Fatty liver"

showing 10 items of 338 documents

Role of Myeloid-Epithelial-Reproductive Tyrosine Kinase and Macrophage Polarization in the Progression of Atherosclerotic Lesions Associated With Non…

2019

Recent lines of evidence highlight the involvement of myeloid-epithelial-reproductive tyrosine kinase (MerTK) in metabolic disease associated with liver damage. MerTK is mainly expressed in anti-inflammatory M2 macrophages where it mediates transcriptional changes including suppression of proinflammatory cytokines and enhancement of inflammatory repressors. MerTK is regulated by metabolic pathways through nuclear sensors including LXRs, PPARs, and RXRs, in response to apoptotic bodies or to other sources of cholesterol. Nonalcoholic fatty liver disease (NAFLD) is one of the most serious public health problems worldwide. It is a clinicopathological syndrome closely related to obesity, insuli…

Drug targeting0301 basic medicineMacrophageMacrophage polarizationInflammationReviewMonocyteProinflammatory cytokine03 medical and health sciencesMerTK0302 clinical medicineFibrosisNonalcoholic fatty liver diseasemedicineNonalcoholic fatty liver diseaseMacrophagePharmacology (medical)InflammationPharmacologybusiness.industrylcsh:RM1-950Lipid metabolismMERTKmedicine.diseasemacrophagesAtherosclerosis; Drug targeting; Inflammation; Macrophages; MerTK; Monocytes; Nonalcoholic fatty liver diseaselcsh:Therapeutics. Pharmacology030104 developmental biologyAtherosclerosi030220 oncology & carcinogenesisCancer researchatherosclerosismedicine.symptommonocytesbusinessFrontiers in Pharmacology
researchProduct

Drug Induced Liver Injury (Dili) and Non Alcoholic Fatty Liver Disease (Nafld)

2020

This review article includes a review of the latest literature searched on PubMed in the field of hepatotoxicity caused by drugs that have a wide daily application. The concept of the review article consists of several parts dealing with the definition of drugs induced liver injury - DILI, diagnostic challenges related to it, and the clinical spectrum of liver disease, with an emphasis on the development of nonalcoholic fatty liver disease - NAFLD and review of drugs involved in formation of NAFLD.

DrugLiver injurymedicine.medical_specialtybusiness.industrymedia_common.quotation_subjectFatty liverNon alcoholicDiseasemedicine.diseaseGastroenterologyReview articleLiver diseaseInternal medicineNonalcoholic fatty liver diseasemedicinebusinessmedia_commonEuropean Journal of Medical and Health Sciences
researchProduct

Antioxidant Therapy and Drugs Interfering with Lipid Metabolism: Could They Be Effective in NAFLD Patients?

2013

This review is part of a special issue dealing with various aspects of non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). We will focus on promising treatments of NASH with antioxidants and drugs that interfere with lipid metabolism.The other therapies of interest, such as diet, behavioral changes, and insulin sensitizers are presented elsewhere. Oxidative stress is believed to play a key role in the pathogenesis of NASH and other liver diseases. Antioxidants aimed at improving chronic alcoholic or viral liver diseases have been an object of study for some time. However, only a few high quality, randomized, versus placebo-controlled, double-blinded trials hav…

DrugPathologymedicine.medical_specialtyCirrhosismedia_common.quotation_subjectDiseaseBioinformaticsAntioxidantsEzetimibeNon-alcoholic Fatty Liver DiseaseDiabetes mellitusHyperlipidemiaDrug DiscoverymedicineHumansmedia_commonPharmacologybusiness.industryFatty livernutritional and metabolic diseasesmedicine.diseaseLipid Metabolismdigestive system diseasesFatty LiverSteatosisAntioxidantbusinessmedicine.drugHumanCurrent Pharmaceutical Design
researchProduct

Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation.

2017

The importance of metabolic syndrome (MetS) lies in its associated risk of cardiovascular disease and type 2 diabetes, as well as other harmful conditions such as nonalcoholic fatty liver disease. In this report, the available scientific evidence on the associations between lifestyle changes and MetS and its components is reviewed to derive recommendations for MetS prevention and management. Weight loss through an energy-restricted diet together with increased energy expenditure through physical activity contribute to the prevention and treatment of MetS. A Mediterranean-type diet, with or without energy restriction, is an effective treatment component. This dietary pattern should be built …

Estils de vidamedicine.medical_specialtylifestyleSíndrome metabòlica -- PrevencióMedicine (miscellaneous)Dietary pattern030209 endocrinology & metabolismDiseaseType 2 diabetes030204 cardiovascular system & hematologypanel recommendationWhole grains03 medical and health scienceschemistry.chemical_compound0302 clinical medicineWeight lossEnvironmental healthCardiovascular DiseaseNonalcoholic fatty liver diseasemedicineHumansLife StyleMetabolic SyndromeNutrition and Dieteticsbusiness.industryFeature ArticleUnsaturated fatPanel recommendationDietary patternmedicine.diseaseLifestyleDietchemistryDiabetes Mellitus Type 2Cardiovascular DiseasesPhysical therapydietary patternMetabolic syndromemedicine.symptombusinessHuman
researchProduct

Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus.

2021

This article also appears in: Health, Medical, and Life Sciences Virtual Issue for Advanced Science.

FGF21General Chemical EngineeringGeneral Physics and AstronomyMedicine (miscellaneous)CODON USAGE BIAS02 engineering and technology01 natural sciencesGLUCOSEACTIVATIONPF-05231023ComputingMilieux_COMPUTERSANDEDUCATIONGeneral Materials SciencegeneticsCells CulturedINSULIN-RESISTANCEFull PaperFatty liverQGeneral Engineeringfibroblast growth factor 21 genetics metabolic metabolic associated fatty liver disease Cells Cultured Enzyme-Linked Immunosorbent Assay Fatty Liver Fibroblast Growth Factors Humans Inflammation LiverFull Papers021001 nanoscience & nanotechnologyPhenotype3. Good healthLiverOBESITY221 Nano-technology0210 nano-technologyReprogrammingEXPRESSIONmedicine.medical_specialtySettore MED/12 - GASTROENTEROLOGIAScienceEnzyme-Linked Immunosorbent Assayfibroblast growth factor 21Biology010402 general chemistryBiochemistry Genetics and Molecular Biology (miscellaneous)metabolic associated fatty liver diseaseInsulin resistancemetabolicInternal medicinemedicineHumansSecretionFGF21 RESISTANCEAlleleInflammationmedicine.disease0104 chemical sciencesFatty LiverFibroblast Growth FactorsEndocrinologyRNA SECONDARY STRUCTURETRANSLATIONHormoneAdvanced science (Weinheim, Baden-Wurttemberg, Germany)
researchProduct

Liver involvement in patients with COVID-19 infection: A comprehensive overview of diagnostic imaging features

2023

During the first wave of the pandemic, coronavirus disease 2019 (COVID-19) infection has been considered mainly as a pulmonary infection. However, different clinical and radiological manifestations were observed over time, including involvement of abdominal organs. Nowadays, the liver is considered one of the main affected abdominal organs. Hepatic involvement may be caused by either a direct damage by the virus or an indirect damage related to COVID-19 induced thrombosis or to the use of different drugs. After clinical assessment, radiology plays a key role in the evaluation of liver involvement. Ultrasonography (US), computed tomography (CT) and magnetic resonance imaging (MRI) may be use…

GastroenterologyAdults X-Ray computed tomography Biliary tract diseases COVID-19 Fatty liver Hepatic infarction Hepatomegaly Infection Liver diseases Magnetic resonance imaging Liver Liver failure Ultrasonography SARS-CoV-2 PediatricsGeneral MedicineSettore MED/36 - Diagnostica Per Immagini E RadioterapiaWorld Journal of Gastroenterology
researchProduct

Alcoholic and Nonalcoholic Liver Disease: Diagnostic Assessment and Therapeutic Perspectives

2019

General Immunology and MicrobiologyArticle Subjectbusiness.industryFatty liverlcsh:RMEDLINElcsh:MedicineGeneral Medicinemedicine.diseaseBioinformaticsAlcoholicGeneral Biochemistry Genetics and Molecular BiologyNOFatty LiverLiver diseaseText miningEditorialNon-alcoholic Fatty Liver DiseaseHumans; Fatty Liver Alcoholic; Non-alcoholic Fatty Liver DiseasemedicineDiagnostic assessmentHumansbusiness
researchProduct

Genetic background in nonalcoholic fatty liver disease: A comprehensive review

2015

In the Western world, nonalcoholic fatty liver disease (NAFLD) is considered as one of the most significant liver diseases of the twenty-first century. Its development is certainly driven by environmental factors, but it is also regulated by genetic background. The role of heritability has been widely demonstrated by several epidemiological, familial, and twin studies and case series, and likely reflects the wide inter-individual and inter-ethnic genetic variability in systemic metabolism and wound healing response processes. Consistent with this idea, genome-wide association studies have clearly identified Patatin-like phosholipase domain-containing 3 gene variant I148M as a major player i…

Genetic MarkersCandidate geneGenome-wide association studieHeredityPatatin-like phospholipase domain-containing 3Genome-wide association studyDiseaseReviewBiologymedicine.disease_causeGeneticNon-alcoholic Fatty Liver DiseaseRisk FactorsHeredityNonalcoholic fatty liver diseasemedicineHumansNonalcoholic fatty liver diseaseGenetic Predisposition to DiseaseGenetic variabilityGenetic associationGeneticsFatty liverGastroenterologyGenetic VariationGeneral Medicinemedicine.diseaseCandidate gene studiePedigreePhenotypeNonalcoholic steatohepatitiTransmembrane 6 superfamily member 2Candidate gene studies; Genetics; Genome-wide association studies; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Patatin-like phospholipase domain-containing 3; Transmembrane 6 superfamily member 2Genome-Wide Association Study
researchProduct

PSD3 downregulation confers protection against fatty liver disease

2022

Fatty liver disease (FLD) is a growing health issue with burdening unmet clinical needs. FLD has a genetic component but, despite the common variants already identified, there is still a missing heritability component. Using a candidate gene approach, we identify a locus (rs71519934) at the Pleckstrin and Sec7 domain-containing 3 (PSD3) gene resulting in a leucine to threonine substitution at position 186 of the protein (L186T) that reduces susceptibility to the entire spectrum of FLD in individuals at risk. PSD3 downregulation by short interfering RNA reduces intracellular lipid content in primary human hepatocytes cultured in two and three dimensions, and in human and rodent hepatoma cell…

GenotypeEndocrinology Diabetes and MetabolismVARIANTSUSCEPTIBILITYPolymorphism Single NucleotideArticleCell LineMiceRibonucleasesPhysiology (medical)Internal MedicineAnimalsGuanine Nucleotide Exchange FactorsHumansRNA-SeqAllelesNon-alcoholic steatohepatitisNONALCOHOLIC STEATOHEPATITISHERITABILITYGene Expression ProfilingfungiNASHGenetic VariationCell BiologyMetabolic syndromeFatty LiverMetabolismGene Expression RegulationLiverEXOME-WIDE ASSOCIATION3121 General medicine internal medicine and other clinical medicineACIDHepatocytesSECRETIONDisease SusceptibilityVLDLBiomarkersTRIGLYCERIDESNon-alcoholic fatty liver disease
researchProduct

Geographic fatty liver deposition in oncologic patient at gray-scale US: role of contrast-enhanced sonography

2014

Geographic fatty livercontrast-enhanced sonography
researchProduct